Sage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial

Amber Tong

When Sage Therapeutics’ star experimental depression drug, zuranolone, failed the crucial MOUNTAIN study, the biotech slammed the brakes on two other pivotal trials in order …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial

Amber Tong

Sign up to read this article for free.

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

Regeneron, two Chinese biotechs tout promise of their hearing loss gene therapies

How AI can address ongoing challenges in the life sciences industry

Sage drops a pair of late-stage tests for Bio­gen-part­nered de­pres­sion drug, rais­ing the stakes on a fi­nal tri­al

Amber Tong

Sign up to read this article for free.

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

Re­gen­eron, two Chi­nese biotechs tout promise of their hear­ing loss gene ther­a­pies

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

Sage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

Regeneron, two Chinese biotechs tout promise of their hearing loss gene therapies

How AI can address ongoing challenges in the life sciences industry